In vitro Comparison of Three Salbutamol-Containing Multidose Dry Powder Inhalers: Buventol Easyhaler, Inspiryl Turbuhaler® and Ventoline Diskus
Authors: Palander A.1; Mattila T.1; Karhu M.1; Muttonen E.1
Source: Clinical Drug Investigation, Volume 20, Number 1, July 2000 , pp. 25-33(9)
Publisher: Adis International
Abstract:
Objective: To compare the in vitro drug delivery characteristics of three salbutamol-containing multidose dry powder inhalers, Buventol Easyhaler, Inspiryl Turbuhaler and Ventoline Diskus.
Materials and Methods: Dose accuracy and consistency, fine particle dose (FPD)/fine particle fraction (FPF), and mass median aerodynamic diameter (MMAD) [measured by Multi-Stage Liquid Impinger] were determined for each inhaler at variable airflow rates (30 and 60 L/min) and at equivalent flow rates (corresponding to a 4kPa pressure drop).
Results: Dose accuracy and consistency (expressed as percentage of label claim) of Easyhaler (mean 95%, SD <4.5% at 30 to 60 L/min) compared favourably with that of Turbuhaler (mean 88%, SD 19% at 60 L/min) and Diskus (mean 93%, SD 8% at 90 L/min). The FPF at an equivalent flow rate was 21% for Easyhaler, 24% for Turbuhaler and 20% for Diskus. The FPF of Turbuhaler was strongly influenced by flow rate (12 to 24% at 30 to 60 L/min), whereas the FPF of Easyhaler (16 to 23% at 30 to 60 L/min) and Diskus (15 to 21% at 30 to 90 L/min) was less variable. MMAD values for Easyhaler and Turbuhaler were stable at flow rates of 30 to 60 L/min, whereas the particle size distribution for Diskus was more dependent on flow rate. Easyhaler had a considerably lower MMAD than Turbuhaler at flow rates of 30 to 60 L/min.
Conclusions: This study demonstrated favourable dose delivery and consistency with Buventol Easyhaler compared with Inspiryl Turbuhaler and Ventoline Diskus. Delivered dose and FPF showed less flow dependency with Easyhaler and Diskus than with Turbuhaler.
Keywords: Antiasthmatics, pharmacodynamics; Inhaler devices; Salbutamol, pharmacodynamics
Language: English
Document Type: Original article
Affiliations: 1: Department of Pharmaceutical Product Development, Orion Corporation, Orion Pharma, Kuopio, Finland *

Click here for Page Help